Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Investment Securities: 2016-2024

Historic Gains from Investment Securities for Arcus Biosciences (RCUS) over the last 9 years, with Dec 2024 value amounting to -$22.0 million.

  • Arcus Biosciences' Gains from Investment Securities fell 500.00% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.0 million, marking a year-over-year increase of 14.29%. This contributed to the annual value of -$22.0 million for FY2024, which is 257.14% down from last year.
  • Latest data reveals that Arcus Biosciences reported Gains from Investment Securities of -$22.0 million as of FY2024, which was down 257.14% from $14.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Gains from Investment Securities registered a high of $14.0 million during FY2023, and its lowest value of -$22.0 million during FY2024.
  • Over the past 3 years, Arcus Biosciences' median Gains from Investment Securities value was $12.0 million (recorded in 2022), while the average stood at $1.3 million.
  • In the last 5 years, Arcus Biosciences' Gains from Investment Securities skyrocketed by 108.79% in 2020 and then tumbled by 257.14% in 2024.
  • Yearly analysis of 5 years shows Arcus Biosciences' Gains from Investment Securities stood at $9.9 million in 2020, then rose by 21.30% to $12.0 million in 2021, then remained steady at $12.0 million in 2022, then climbed by 16.67% to $14.0 million in 2023, then plummeted by 257.14% to -$22.0 million in 2024.